Seminars in thrombosis and hemostasis最新文献_第2页

Monitoring Hemostatic Function during Cardiac Surgery with Point-of-Care Viscoelastic Assays: A Narrative Review. 监测心脏手术中的止血功能与护理点粘弹性分析：叙述性回顾。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-06-01 Epub Date: 2025-02-12 DOI: 10.1055/s-0045-1802573

Brandon Jin An Ong, Hui Xin See Tow, Alyssa Tze Wei Fong, Ryan Ruiyang Ling, Kiran Shekar, Kristine Teoh, Lian Kah Ti, Graeme MacLaren, Bingwen Eugene Fan, Kollengode Ramanathan

{"title":"Monitoring Hemostatic Function during Cardiac Surgery with Point-of-Care Viscoelastic Assays: A Narrative Review.","authors":"Brandon Jin An Ong, Hui Xin See Tow, Alyssa Tze Wei Fong, Ryan Ruiyang Ling, Kiran Shekar, Kristine Teoh, Lian Kah Ti, Graeme MacLaren, Bingwen Eugene Fan, Kollengode Ramanathan","doi":"10.1055/s-0045-1802573","DOIUrl":"10.1055/s-0045-1802573","url":null,"abstract":"Abstract: Bleeding is a well-known and severe complication of cardiac surgery. Cardiopulmonary bypass, along with heparinization and hemodilution, is thought to affect all pathways of the hemostatic process, leading to excessive bleeding and worsened morbidity and mortality. The traditionally used standard laboratory tests (SLTs) were not designed for the surgical setting, have long turnaround times, and are poor predictors of bleeding. This review aims to give an overview of viscoelastic assays (VEAs), compare VEAs to conventional testing methods, and summarize the evidence for VEAs in cardiac surgery. A search of Medline via Pubmed, Scopus, and Embase yielded 2,868 papers, which we reviewed and summarized the key findings. VEAs such as rotational thromboelastometry and thromboelastography provide a quick turnaround, graphical, global impression of hemostasis in whole blood. VEAs allow for the analysis of specific contributors to the coagulation process and may facilitate cause-oriented hemostatic treatment and the development of treatment algorithms. VEAs have been found to have a high specificity and high negative predictive value for coagulopathic bleeding. Patients treated with VEA-based algorithms have been shown to have lower rates of bleeding, transfusion requirements, and exposure to allogeneic blood products. However, VEA-based algorithms have not demonstrated a mortality benefit and evidence for outcomes such as surgical re-exploration and hospital length of stay remains equivocal. In conclusion, VEAs have been shown to be comparable if not superior to SLTs in cardiac surgery. Further large-scale studies are needed to better evaluate the impact of VEAs on clinical outcomes.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"417-429"},"PeriodicalIF":4.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent Bleeding after Cervical Surgery with Quebec Platelet Disorder: Case Report and Literature Review. 宫颈手术后复发出血合并魁北克血小板紊乱：病例报告及文献复习。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-05-08 DOI: 10.1055/a-2859-5475

Yang Su, Cheng Liu, Yao Wei, Xiaolong Ma, Yongxin Li, Rui Qiao

引用次数: 0

Therapeutic Interventions for Obstetric Antiphospholipid Syndrome Associated with Recurrent Pregnancy Loss: A Scoping Review of Randomized Controlled Trials on Live Birth Outcomes. 与复发性妊娠丢失相关的产科抗磷脂综合征的治疗干预：对活产结局的随机对照试验的范围回顾

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-05-05 DOI: 10.1055/a-2866-2950

Buse Bor, Karen Schreiber, Bent Winding Deleuran, Mustafa Vakur Bor

{"title":"Therapeutic Interventions for Obstetric Antiphospholipid Syndrome Associated with Recurrent Pregnancy Loss: A Scoping Review of Randomized Controlled Trials on Live Birth Outcomes.","authors":"Buse Bor, Karen Schreiber, Bent Winding Deleuran, Mustafa Vakur Bor","doi":"10.1055/a-2866-2950","DOIUrl":"https://doi.org/10.1055/a-2866-2950","url":null,"abstract":"Antiphospholipid syndrome (APS) is an autoimmune disease defined by thrombotic or obstetrical clinical manifestations and the persistent presence of antiphospholipid antibodies, including lupus anticoagulant, anticardiolipin antibodies and anti-beta2-glycoprotein 1 antibodies. Obstetric APS (OAPS) is associated with pregnancy morbidity, including early recurrent pregnancy loss (RPL), preeclampsia, premature birth and stillbirth. Treatment regimens for women with OAPS are designed to optimise pregnancy outcomes. It is still debated which intervention results in the most optimal pregnancy outcome. This scoping review examines treatment options for women with OAPS presenting with RPL based solely on randomized controlled trials (RCTs) reporting pregnancy outcomes. A systematic search identified 1,234 studies published up to January 2026, from which 14 RCTs met the inclusion criteria: pregnant women with APS defined as persistent aPL positivity and RPL (≥2) receiving therapeutic intervention with live birth as the primary outcome. These RCTs, published between 1992 and 2017, included 1,878 participants. Secondary outcomes, including birth weight, preeclampsia, preterm delivery, and bleeding were also analyzed. Different treatment options such as low-dose aspirin (LDA), unfractionated heparin, low molecular weight heparin (LMWH), corticosteroids and intravenous immunoglobulin were used in the clinical trials. Antithrombotic therapy (LDA+LMWH) was associated with higher live birth rates compared with the other evaluated strategies. However, this finding is based on a small number of heterogeneous RCTs and is disproportionately driven by a single large trial. Consequently, substantial uncertainty remains. High-quality, adequately powered RCTs are urgently needed to provide robust evidence for optimal OAPS management.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147842565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood Flow Restriction Training in Athletes: Endothelial Phenotype, Thromboembolism Risk, and Tailored Safety Protocols. 运动员的血流限制训练：内皮表型、血栓栓塞风险和量身定制的安全方案。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-28 DOI: 10.1055/a-2863-5770

Dahan da Cunha Nascimento, Karla Helena Coelho Vilaça E Silva

{"title":"Blood Flow Restriction Training in Athletes: Endothelial Phenotype, Thromboembolism Risk, and Tailored Safety Protocols.","authors":"Dahan da Cunha Nascimento, Karla Helena Coelho Vilaça E Silva","doi":"10.1055/a-2863-5770","DOIUrl":"https://doi.org/10.1055/a-2863-5770","url":null,"abstract":"Low-load blood flow restriction (LLBFR) training has gained traction as a rehabilitation and performance tool, offering muscle strength and hypertrophy adaptations comparable to high-load resistance training (HLRT) while minimizing joint and tissue stress. However, its application in athletes at risk for venous thromboembolism (VTE), post-thrombotic syndrome (PTS), inherited thrombophilia, and special populations (pregnant competitive female athletes and Paralympic athletes with spinal cord injury) raises safety concerns. This narrative review synthesizes evidence on LLBFR's hemodynamic and endothelial effects, highlighting pressure-dependent basal lamina thickening, impaired flow-mediated dilation, and transient elevations in peripheral venous pressure (PVP). It emphasizes the importance of pre-exercise risk stratification, genetic screening for factor V Leiden and prothrombin mutations, and assessment of cardiovascular and coagulation markers. For athletes with confirmed DVT, PTS, or multiple risk factors, LLBFR should be contraindicated. In Paralympic athletes with spinal cord injury, stringent exclusion criteria (e.g., severe autonomic dysreflexia, pressure ulcers) are essential, while female athletes may require individualized monitoring of coagulation changes during oral contraceptive use and pregnancy. Although LLBFR shows promise for preserving muscle function when traditional loading is impractical, robust, large-scale studies measuring thrombogenesis and fibrinolysis markers are urgently needed. Tailored protocols that balance musculoskeletal benefits against thrombotic risks will ensure safe, effective implementation across diverse athlete populations.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147780066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring haemostatic function during extracorporeal membrane oxygenation with point-of-care viscoelastic assays: a narrative review. 监测止血功能在体外膜氧合与点护理粘弹性测定：叙述性回顾。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-23 DOI: 10.1055/a-2859-5556

Saikat Mitra, Christopher Low, Brandon Ong, Ryan Ruiyang Ling, Kiran Shekar, Graeme MacLaren, Bingwen Eugene Fan, Kollengode Ramanthan

{"title":"Monitoring haemostatic function during extracorporeal membrane oxygenation with point-of-care viscoelastic assays: a narrative review.","authors":"Saikat Mitra, Christopher Low, Brandon Ong, Ryan Ruiyang Ling, Kiran Shekar, Graeme MacLaren, Bingwen Eugene Fan, Kollengode Ramanthan","doi":"10.1055/a-2859-5556","DOIUrl":"https://doi.org/10.1055/a-2859-5556","url":null,"abstract":"Extracorporeal membrane oxygenation (ECMO) has increasingly been used in patients with refractory severe cardiorespiratory failure in the recent years. The use of ECMO necessitates anticoagulation as blood passes through an extracorporeal circuit that has a membrane lung and a centrifugal pump. Although heparin is the most common anticoagulant used during ECMO runs, other anticoagulants like direct thrombin inhibitors and Factor X inhibitors have also been implemented in special circumstances. Bleeding is a well-known and severe complication while receiving ECMO and balancing this against circuit thrombosis is a clinical challenge. While standard laboratory tests such as activated partial thromboplastin time and point of care tests such as activated clotting time help monitor anticoagulation on ECMO, they have their drawbacks. The use of viscoelastic assays (VEAs) in aiding anticoagulation management on ECMO has shown some benefits in reducing bleeding and thrombotic complications, though these assays are not widely used at present. This article explores the challenges of monitoring anticoagulation on ECMO and reviews the available evidence regarding VEAs in adult and paediatric ECMO.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147780127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red Blood Cell Piezo1 Activation Drives Faster Coagulation and Structural Alterations in Blood Clots through Red Blood Cell Deformability Impairment. 红细胞Piezo1激活通过红细胞变形性损伤驱动更快的凝血和血凝块结构改变。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-15 DOI: 10.1055/a-2846-3643

Bita Asghariastanehei, Marie Martin, Elie Nader, Hamdi Rezigue, Anaëlle de Wreede, Yesim Dargaud, Christophe Nougier, Philippe Joly, Angélica Niñoé, Stéphane Egée, Lars Kaestner, Philippe Connes

{"title":"Red Blood Cell Piezo1 Activation Drives Faster Coagulation and Structural Alterations in Blood Clots through Red Blood Cell Deformability Impairment.","authors":"Bita Asghariastanehei, Marie Martin, Elie Nader, Hamdi Rezigue, Anaëlle de Wreede, Yesim Dargaud, Christophe Nougier, Philippe Joly, Angélica Niñoé, Stéphane Egée, Lars Kaestner, Philippe Connes","doi":"10.1055/a-2846-3643","DOIUrl":"10.1055/a-2846-3643","url":null,"abstract":"Red blood cells (RBCs) must be highly deformable to pass through capillaries narrower than their own diameter for delivering oxygen to the tissues. Ion channels are central regulators of RBC deformability and volume. Gain-of-function mutations in Piezo1, as seen in hereditary xerocytosis, cause RBC dehydration and have been associated with an increased risk of thromboembolism. Here we investigated how pharmacological RBC-Piezo1 activation affects RBC membrane potential, RBC ion content, RBC deformability, coagulation dynamics, and clot structure.Blood samples were collected from healthy donors. RBCs were isolated and incubated with Yoda1, a drug known to activate Piezo1. Membrane potential was measured using the Macey-Bennekou-Egée method. Intracellular Na+/K+ content was determined by flame photometry. RBC deformability was measured by ektacytometry. Coagulation dynamics were investigated by rotational thromboelastometry, and clot structure was observed by electron microscopy.Yoda1 treatment led to RBC membrane hyperpolarization, reduced cell volume, a decrease in intracellular K+, an increase in Na+, and a reduction in RBC deformability. ROTEM analysis showed shorter clotting and lysis times in Yoda1-treated samples compared with samples treated with the vehicle (control condition), independently of RBC phosphatidylserine exposure. Electron microscopy revealed structural alterations in Yoda1-treated samples, with less compacted RBCs.Altogether, these findings indicate that Piezo1 activation disrupted RBC ion balance and membrane potential, leading to dehydration and decreased deformability. These alterations contributed to accelerated coagulation and compromised clot structure, suggesting a potential role of Piezo1 in modulating thrombotic risk in RBC-related disorders.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating Next-Generation Sequencing into von Willebrand Disease Diagnostics: Insights from the PCM-EVW-ES Multicenter Project. 将下一代测序整合到血管性血友病诊断中：来自PCM-EVW-ES多中心项目的见解

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-15 DOI: 10.1055/a-2845-0281

Nina Borràs, Irene Corrales, Francisco Vidal

{"title":"Integrating Next-Generation Sequencing into von Willebrand Disease Diagnostics: Insights from the PCM-EVW-ES Multicenter Project.","authors":"Nina Borràs, Irene Corrales, Francisco Vidal","doi":"10.1055/a-2845-0281","DOIUrl":"https://doi.org/10.1055/a-2845-0281","url":null,"abstract":"Von Willebrand disease (VWD) is the most common inherited bleeding disorder, caused by quantitative or qualitative defects in von Willebrand factor (VWF). Diagnosis is challenging and requires integrating bleeding history, VWF antigen and activity measurements, FVIII assays, and specialized phenotyping. Genetic testing is increasingly recognized as a key component. Here, we review current concepts in VWD diagnostics and highlight the Spanish Clinical and Molecular Profile of von Willebrand Disease (PCM-EVW-ES) project as a model for genomics-enabled precision medicine. PCM-EVW-ES is a multicenter initiative involving 48 hospitals, centralized phenotypic testing, and next-generation sequencing of the VWF coding region, enabling definitive classification in 730 individuals with VWD to date. Harmonized recruitment criteria and standardized workflows improve subtype assignment, uncover complex genotypes, refine genotype-phenotype correlations, and facilitate the identification of asymptomatic carriers. The PCM-EVW-ES variant spectrum highlights recurrent disease-causing variants in Spain and underscores the value of coordinated national registries for variant curation. Building on these data, we propose a diagnostic algorithm in which bleeding assessment and first-line VWF/FVIII assays, combined with, early VWF molecular testing increases diagnostic accuracy and guides targeted second-line investigations to confirm and refine VWD subtype classification. We also outline persisting challenges, including the interpretation of variants of uncertain significance and patients without identifiable pathogenic VWF variants, and future directions integrating third-generation sequencing, expanded gene panels, functional studies, and artificial-intelligence-driven multiomic approaches. Together, these advances illustrate how robust multicenter studies can bridge the gap between complex diagnostics and clinical practice in VWD.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147692116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Circulating Extracellular Vesicles in Hemophilia. 循环细胞外囊泡在血友病中的作用。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-14 DOI: 10.1055/a-2845-0232

Roza Chaireti, Jovan P Antovic, Iva Pruner

{"title":"The Role of Circulating Extracellular Vesicles in Hemophilia.","authors":"Roza Chaireti, Jovan P Antovic, Iva Pruner","doi":"10.1055/a-2845-0232","DOIUrl":"https://doi.org/10.1055/a-2845-0232","url":null,"abstract":"Hemophilia is a rare inherited bleeding disorder caused by a deficiency of factor VIII or IX, leading to insufficient thrombin generation and impaired clot formation. While advances in replacement and nonfactor therapies have improved patient outcomes, challenges such as inhibitor development, joint disease, and breakthrough bleeding persist. Extracellular vesicles (EVs) are small membrane-bound particles released from all kinds of cells and have emerged as key mediators of coagulation, vascular integrity, and immune responses. In hemophilia, EVs provide procoagulant surfaces, carry tissue factor and phosphatidylserine, and may stabilize clot structure, partially compensating for deficient coagulation. Clinical studies further suggest that EV levels and composition are altered by factor replacement or bypassing agents, indicating their role as biomarkers of treatment response. Beyond their diagnostic potential, engineered EVs are being explored as innovative therapeutic tools capable of delivering clotting factors and modulating joint inflammation. This review outlines current knowledge on circulating EVs in hemophilia, emphasizing their mechanistic roles, clinical evidence, and therapeutic potential.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147692107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom. Emicizumab治疗获得性血友病A：英国单一血友病综合护理中心的经验。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-14 DOI: 10.1055/a-2836-0591

Olga S Tatarinova, Philippa Woolley, Nilanthi Karawitage, Saravanan Vinayagam, Karen Logan, Catherin Ryu, George Adams, Carolyn Millar, Mike Laffan, Ferras Alwan, Deepa J Arachchillage

{"title":"Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.","authors":"Olga S Tatarinova, Philippa Woolley, Nilanthi Karawitage, Saravanan Vinayagam, Karen Logan, Catherin Ryu, George Adams, Carolyn Millar, Mike Laffan, Ferras Alwan, Deepa J Arachchillage","doi":"10.1055/a-2836-0591","DOIUrl":"https://doi.org/10.1055/a-2836-0591","url":null,"abstract":"Acquired haemophilia A (AHA) is an autoimmune bleeding disorder mediated by the production of autoantibody inhibitors against factor VIII (FVIII), resulting in a bleeding phenotype. The standard treatment of AHA includes immunosuppressive therapy for inhibitor eradication, haemostatic treatment with FVIII bypassing agents and treatment of underlying causes. Emicizumab is a bispecific monoclonal antibody that restores the function of missing activated FVIII by bridging FIXa and FX. Emicizumab is successfully used for prophylaxis of bleeding in congenital haemophilia A patients with or without FVIII inhibitors; however, it is not licensed for AHA treatment in the United Kingdom. We summarise our single-centre experience of the use of emicizumab for the treatment of AHA in 10 patients in the United Kingdom. Emicizumab was started at a dose of 3 mg/kg weekly with a change to fortnightly after the fourth dose. Eight patients received a combination of corticosteroids, emicizumab and rituximab; the remaining two, emicizumab and corticosteroids. In seven patients, emicizumab was stopped after achievement of an FVIII response and haemostasis following a median of 7 doses (3-53). In one patient, the treatment with emicizumab was complicated by the development of microangiopathic haemolytic anaemia. Three patients died, and in two of them, the death was associated with bleeding.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147692043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Case of Acquired Non-neutralizing Factor II Inhibitor in a Patient with B-Cell Lymphoproliferative Disorder. 一例罕见的获得性非中和因子II抑制剂治疗b淋巴细胞增生性疾病。

IF 4.1 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2026-04-09 DOI: 10.1055/a-2845-0155

Ciro Miele, Chiara Caputo, Ilenia Lorenza Calcaterra, Paolo Conca, Ernesto Cimino, Martina Romeo, Greta Chiarelli, Raffaele Russo, Guido D'Errico, Carmine De Luca, Martina Aversano, Miriam Mazzone, Eleonora Franco, Luigi Jr Valletta, Cristina Mazzaccara, Matteo Di Minno, Antonella Tufano

引用次数: 0